Oryzon
Manufacturing · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Sant Ferran Cornella De Llobregat 74, Co...Phone Number
+34 935151313Website
www.oryzon.comRevenue
$9.3 MillionStock Symbol
ORYIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company. Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon is headquartered in Catalonia, Spain.Explore more
Oryzon Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oryzon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Oryzon had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Oryzon has new funding data
Congratulate Masked Content for being promoted to Masked Content at Oryzon
Check out if Oryzon is spiking on competitors!
Earning: See what the market has to say on Oryzon recently announced quarterly report
Website visits: Recent activity has been detected on your website
Oryzon, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Oryzon has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Oryzon launches new products
Recommended Actions
Reach out to Masked Content who joined Oryzon as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Oryzon is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oryzon is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oryzon.
Oryzon financials insights
Gather financial insights about Oryzon, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2003
Series A
$1.3M
2008
Series B
$17M
2016
Debt
$12.1M
Debt
$6M
2017
Other Financing Round
$18M
2022
Debt
$8.2M
2025
Share Placement
$34M
Oryzon Tech Stack
A closer look at the technologies used by Oryzon
Most Recent Scoops
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals
New Hire
Executive Move
Executive Moves, New Hire
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Oryzon News & Media
ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
MADRID and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the first patient has been enrolled in IDEAL, its Phase II study evaluating iadademstat in patients with essential thrombocythemia (ET).ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026
MADRID and CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended March 31, 2026, and provided a corporate update on recent developments.ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026
MADRID and CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that updated positive clinical data from two Phase Ib clinical trials evaluating its selective LSD1 inhibitor iadademstat in acute myeloid leukemia (AML) will be presented in two poster sessions at the European Hematology Association (EHA) Annual Congress, taking place June 11-14, 2026 inORYZON to Participate in Upcoming Events in May and June
MADRID and CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that it will participate at the following upcoming events:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oryzon
Sign Up For FreeTo access detailed company insights
Founded in 2000 in Barcelona, Spain, Oryzon is a clinical stage biopharmaceutical company. Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon is headquartered in Catalonia, Spain.... Read More
